scholarly journals Autologous Dendritic Cell-Autologous Tumor mRNA-Human CD40L Vaccine

2020 ◽  
Author(s):  
Keyword(s):  
Dendritic Cell ◽  
Autologous Tumor ◽  
Autologous Dendritic Cell ◽  
Tumor Mrna

scholarly journals Blood Eosinophilia Is an on-Treatment Biomarker in Patients with Solid Tumors Undergoing Dendritic Cell Vaccination with Autologous Tumor-RNA

Pharmaceutics ◽  
2020 ◽  
Vol 12 (3) ◽  
pp. 210 ◽  
Author(s):  
Alvaro Moreira ◽  
Michael Erdmann ◽  
Ugur Uslu ◽  
Verona Vass ◽  
Gerold Schuler ◽  
...  
Keyword(s):  
Dendritic Cell ◽  
Solid Tumors ◽  
Checkpoint Inhibitors ◽  
Dendritic Cell Vaccination ◽  
Autologous Tumor ◽  
Blood Eosinophilia ◽  
Significant Difference ◽  
Eosinophil Counts ◽  
Tumor Mrna

Background: The approvals of immune checkpoint inhibitors for several cancer types and the rapidly growing recognition that T cell-based immunotherapy significantly improves outcomes for cancer patients led to a re-emergence of cancer vaccines, including dendritic cell (DC)-based immunotherapy. Blood and tissue biomarkers to identify responders and long-term survivors and to optimize cost and cost-effectiveness of treatment are greatly needed. We wanted to investigate whether blood eosinophilia is a predictive biomarker for patients with solid tumors receiving vaccinations with DCs loaded with autologous tumor-RNA. Methods: In total, 67 patients with metastatic solid tumors, who we treated with autologous monocyte-derived DCs transfected with total tumor mRNA, were serially analyzed for eosinophil counts and survival over the course of up to 14 years. Eosinophilic counts were performed on peripheral blood smears. Results: Up to 87% of the patients treated with DC-based immunotherapy experienced at least once an eosinophilia of ≥ 5% after initiation of therapy; 61 % reached levels of ≥ 10% eosinophils, and 13% of patients showed eosinophil counts of 20% or above. While prevaccination eosinophil levels were not associated with survival, patients with blood eosinophilia at any point after initiation of DC-based immunotherapy showed a trend towards longer survival. There was a statistically significant difference for the patients with eosinophil counts of 20% or more (p = 0.03). In those patients, survival was prolonged to a median of 58 months (range 2–111 months), compared to a median of 20 months (range 0–119 months) in patients with lower eosinophil counts. In 12% of the patients, an immediate increase in eosinophil count of at least 10 percentage points could be detected after the first vaccine, which also appeared to correlate with survival (65 vs. 24 months; p = 0.06). Conclusion: Blood eosinophilia appears to be an early, on-therapy biomarker in patients with solid tumors undergoing vaccination with RNA-transfected DC, specifically autologous tumor mRNA-transfected DC vaccines, and it correlates with long-term patient outcome. Eosinophilia should be systematically investigated in future trials.

scholarly journals FRET microscopy autologous tumor lysate processing in mature dendritic cell vaccine therapy

2010 ◽  
Vol 8 (1) ◽  
pp. 52 ◽  
Author(s):  
Laura Fiammenghi ◽  
Valentina Ancarani ◽  
Tilman Rosales ◽  
Jay R Knutson ◽  
Massimiliano Petrini ◽  
...  
Keyword(s):  
Dendritic Cell ◽  
Dendritic Cell Vaccine ◽  
Vaccine Therapy ◽  
Cell Vaccine ◽  
Autologous Tumor ◽  
Mature Dendritic Cell ◽  
Tumor Lysate

scholarly journals Human Anergic CD4+ T Cells Can Act as Suppressor Cells by Affecting Autologous Dendritic Cell Conditioning and Survival

2002 ◽  
Vol 168 (3) ◽  
pp. 1060-1068 ◽  
Author(s):  
Loredana Frasca ◽  
Cristiano Scottà ◽  
Giovanna Lombardi ◽  
Enza Piccolella
Keyword(s):  
T Cells ◽  
Dendritic Cell ◽  
Cd4 T Cells ◽  
Suppressor Cells ◽  
Autologous Dendritic Cell
Sign in / Sign up

Export Citation Format

Share Document